Article Sidebar

PDF
Date Published: 11/01/2024
Abstract Views: 131
Views PDF: 87
DOI: https://doi.org/10.51298/vmj.v533i2.7968
Issue
Vol. 533 No. 2 (2023)
Section
Các bài báo
How to Cite
Nguyễn, T. N. H., & Nguyễn, D. H. . (2024). CURRENT STATUS OF NON RESPONSE TO INFLIXIMAB IN ANKYLOSING SPONDYLITIS MANAGEMENT. Vietnam Medical Journal, 533(2). https://doi.org/10.51298/vmj.v533i2.7968

CURRENT STATUS OF NON RESPONSE TO INFLIXIMAB IN ANKYLOSING SPONDYLITIS MANAGEMENT

Thị Như Hoa Nguyễn, Duy Hiệp Nguyễn

Main Article Content

Abstract

Aims: To determine the prevalence of non - response to  infliximab and other factors related to the non – response to infliximab in Ankylosing spondylitis patients. Subjects and methods: longitudinal, descriptive study in patients received infliximab in Ankylosing spondylitis at Bach Mai Hospital from August 2018 to August 2022. Results: In this study of 74 patients (87,8% male, 29,4 ± 11,8 years of age) ankylosing spondylitis patients in the study, which included primary lack of response PLR (5; 6,8%), secondary lack of response SLR (26; 35,1%) and responders (43; 58,1%). The secondary non-responders had a greater prevalence of medication non-adherence than the responders to infliximab. Conclusions: Non - response to  infliximab in Ankylosing spondylitis patients: 41,9%. The secondary non-responders had a greater prevalence of medication non-adherence than the responders to infliximab.

Article Details

References

1. Ulus Y, Akyol Y, Bilgici A, Kuru O. Association of work instability with fatigue and emotional status in patients with ankylosing spondylitis: comparison with healthy controls. Clin Rheumatol. 2019; 38(4):1017-1024. doi:10.1007/s10067-018-4366-x
2. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res. 2019;71(10):1285-1299. doi:10.1002/ acr.24025
3. Liu W, Wu Y hao, Zhang L, et al. Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis. Sci Rep. 2016;6:32768. doi:10.1038/srep32768
4. Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017;47(3): 343-350. doi: 10.1016 /j.semarthrit. 2017.04.005
5. Alazmi M, Sari I, Krishnan B, Inman RD, Haroon N. Profiling Response to Tumor Necrosis Factor Inhibitor Treatment in Axial Spondyloarthritis. Arthritis Care Res. 2018;70(9):1393-1399. doi:10.1002/acr.23465
6. Wang R, Dasgupta A, Ward MM. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis. JAMA Netw Open. 2022;5(3): e222312. doi:10.1001/ jamanetworkopen. 2022.2312
7. Lindström U, Olofsson T, Wedrén S, Qirjazo I, Askling J. Biological treatment of ankylosingspondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice. Arthritis Res Ther. 2019;21(1):128. doi:10.1186/ s13075-019-1908-9
8. Plasencia C, Pascual-Salcedo D, Nuño L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71(12):1955-1960. doi: 10.1136/annrheumdis-2011-200828